Ciprofloxacin resistance is common both among animal and human Campylobacter jejuni isolates. Resistant isolates are shown to persist even without selection pressure. To obtain further insight on effects of ciprofloxacin exposure on C. jejuni we compared transcriptional responses of both C. jejuni wild-type strain 81-176 (ciprofloxacin MIC 0.125 mg l ) and its intermediate ciprofloxacin-resistant variant P3 (Asp90AAsn in GyrA) in the absence and presence of ciprofloxacin. Further, we sequenced the genome of P3 and compared the sequence with that of wild-type 81-176. One hour of exposure to 8 mg l "1 of ciprofloxacin did not decrease the viability of the parent strain 81-176. Transcriptional analysis revealed that ciprofloxacin exposure caused changes in the expression of genes involved in DNA replication and repair. While in the wild-type the exposure caused downregulation of several genes involved in the control of DNA replication and recombination, the genes controlling nucleotide excision repair and DNA modification were upregulated in both the wild-type and P3. In addition, we observed that ciprofloxacin exposure caused upregulation of genes responsible for damage recognition in base excision repair in P3. In contrast, without ciprofloxacin exposure, DNA repair mechanisms were substantially downregulated in P3. The genome sequence of P3 compared to that of the 81-176 parental strain had three non-synonymous substitutions and a deletion, revealing that the resistant variant had maintained genetic integrity. In conclusion, enhanced DNA repair mechanisms under ciprofloxacin exposure might explain maintenance of genomic integrity in ciprofloxacin-resistant variant P3.
INTRODUCTION
Campylobacter jejuni is one of the most important zoonotic enteric bacterial human pathogens and colonizes the gastrointestinal tract of various animals. The number of Campylobacter infections has increased worldwide, raising concern regarding the high levels of fluoroquinolone resistance observed in C. jejuni isolates in particular (Luo et al., 2005) . Furthermore, as fluoroquinolone resistance has been reported to persist in C. jejuni populations, the use of ciprofloxacin in severe human campylobacteriosis might be compromised in the future (Nelson et al., 2007) .
Fluoroquinolones, including ciprofloxacin, influence bacterial DNA metabolism by blocking DNA replication and transcription (Drlica & Zhao, 1997; Drlica et al., 2009) . In Gram-negative bacteria the target mutations increasing ciprofloxacin resistance have been associated with DNA gyrase (gyrA and gyrB; topoisomerase II) and topoisomerase IV (parC and parE). C. jejuni is an exceptional bacterium, as high-level resistance to ciprofloxacin requires only mutation(s) in the quinolone resistance determining region (QRDR) of the gyrA gene, but not in the gyrB gene (Payot et al., 2002; Piddock et al., 2003) . In addition, homologues of the parC or parE genes do not exist in C. jejuni genomes (Parkhill et al., 2000) . The most common mutation in GyrA is the amino acid substitution Thr86AIle, and the less frequent Asp90AAsn and Ala70AThr have been described (Beckmann et al., 2004; Luo et al., 2003; Payot et al., 2002; Piddock et al., 2003; Wang et al., 1993) . Rapidly evolving ciprofloxacin-resistant C. jejuni mutants have been suggested to exhibit enhanced fitness and competitive advantage when compared to susceptible C. jejuni populations (Luo et al., 2005) . The resistance of C. jejuni to ciprofloxacin is also modulated by the CmeABC efflux pump system that forms a membrane channel and extrudes toxic substrates directly out of the bacterial cell (Lin et al., 2002; Luo et al., 2003) .
Global transcriptome analysis has been reported for several fluoroquinolone resistant human pathogens (Cirz et al., 2006 (Cirz et al., , 2007 Dorer et al., 2010; Gmuender et al., 2001; Marrer et al., 2006) . These transcriptome studies have shown that responses to ciprofloxacin exposure involve DNA-damage repair mechanisms through the SOS response (Kuzminov, 1999) . However, C. jejuni lacks LexA (Han et al., 2008) , which is important in SOSmediated DNA repair and thus a typical SOS response system is not functional in C. jejuni. It is not known which molecular mechanisms underlying responses to ciprofloxacin cause direct DNA damage, like DNA breaks and fragmentation. Based on a gene expression study of C. jejuni NCTC 11168, ciprofloxacin exposure can cause various responses in general cellular processes, but only two factors were directly associated with DNA metabolism (Han et al., 2008) : downregulation of the DNA polymerase subunit dnaE and upregulation of the mdf gene. The transcriptional-repair coupling factor Mdf functions in strand-specific DNA repair and it was suggested to contribute to the emergence of ciprofloxacin-resistant mutants (Han et al., 2008) . Another recent study by Gaasbeek et al. (2009) that employed insertional mutants of uvrB, ung, recA, and mutS proved that nucleotide excision repair (NER) and RecA-dependent recombinational repair were functional DNA repair systems in C. jejuni (Gaasbeek et al., 2009; Guerry et al., 1994) . In addition, the Ung glycosylase acting in base excision repair (BER) was active, but the methyl-directed mismatch repair (MMR) system was suggested to be non-functional (Gaasbeek et al., 2009) . Currently, although the mechanisms of DNA uptake, competence and transformation have been studied with naturally transformable C. jejuni, the multiple factors participating in the above-mentioned DNA repair mechanisms are mostly uncharacterized (Gaasbeek et al., 2009; Gilbreath et al., 2011) .
Here we present results of an investigation into the differences in gene expression between the wild-type C. jejuni 81-176 and its ciprofloxacin-resistant variant. The differentially expressed genes were determined in the absence and presence of ciprofloxacin. After 1 h of ciprofloxacin exposure, the viability of the C. jejuni 81-176 wild-type was unexpectedly high. We showed that under ciprofloxacin unexposed growth conditions, the expression of DNA replication and repair genes were downregulated in the intermediate-resistant variant when compared to the wild-type. Secondly, a set of genes involved in DNA metabolism responded to a high level of ciprofloxacin exposure in the wild-type C. jejuni. In addition, our results show that ciprofloxacin exposure activates the DNA repair systems in the resistant variant, which potentially indicates a necessary response to maintain genetic integrity and which is involved in fitness.
METHODS
Bacterial strains and growth conditions. C. jejuni 81-176, its ciprofloxacin-resistant variant (hereafter designated P3, see below) and ATCC 33560 were maintained in Mueller-Hinton (MH) broth (Difco) supplemented with 20 % (v/v) glycerol at 270 uC and cultivated on Nutrient agar (Oxoid) or MH agar supplemented with 5 % of blood at 37 uC in microaerobic conditions (6 % O 2 , 10 % CO 2 , 84 % N 2 ). All bacterial cultures were grown in MH broth at 37 uC in a microaerobic atmosphere with agitation at 100 r.p.m. For RNA isolation, strains were subcultivated twice in MH broth and subsequently inoculated into 250 ml MH broth with a starting inocula of 10 6 c.f.u. ml 21 . Growth was monitored by both c.f.u. determination and OD 600 measurements during the exponential growth phase.
Selection and characterization of an in vitro ciprofloxacinresistant variant. The ciprofloxacin-resistant variant was obtained from C. jejuni 81-176 exposed to 0.125 mg l 21 (16 MIC) ciprofloxacin as previously described (Hannula & Hänninen, 2008) . A colony selected from MH blood agar plates containing antibiotic was further subcultivated without selection on MH blood agar. MICs were determined by the agar dilution method, using C. jejuni ATCC 33560 as the control strain (Hannula & Hänninen, 2008) . The sequence of the QRDR of gyrA of P3 was determined by PCR amplifying a fragment of 496 bp with primers gyrAHHF and gyrAHHR and sequenced by primers gyrAF and Cjc-R (Table S1 , available in Microbiology Online). The genomic sequence of the P3 variant was determined using Illumina sequencing technology (100 cycles, paired-end library, 8606 coverage; performed by Base-Clear BV). Reads were filtered using the Condetri perl script (Smeds & Künstner, 2011 ) (default settings, minimum read length of 75 nt) and only sequences passing the quality threshold in both paired reads were aligned to the C. jejuni 81-176 entry using Bowtie2 (Langmead & Salzberg, 2012) as part of the breseq-pipeline (Barrick et al., 2009) as well as MIRA (Chevreux et al., 1999) . Polymorphic sites detected by both approaches were manually validated and sites resulting from ambiguously mapped reads were not taken into account.
RNA isolation and purification. For RNA isolation, five independent experiments with and without ciprofloxacin were performed for 81-176 and the P3 variant. Briefly, bacteria grown for 16 h in MH broth were divided into two equal portions of 125 ml. Unexposed control and broth with added ciprofloxacin (8 mg l
21
) were further incubated at 37 uC in a microaerobic atmosphere with agitation at 100 r.p.m. After 1 h, bacterial cells (10 ml) were immediately mixed with two volumes of an RNA stabilization reagent, RNAprotect Bacteria Reagent (Qiagen). The samples were further processed according to manufacturer's instructions (Qiagen) and stored at 270 uC until RNA extraction. Total RNA was extracted using an RNeasy Mini kit according to the manufacturer's instructions (Qiagen). A second DNase treatment with 2 U of TURBO DNase (Ambion) was performed following an RNA cleanup using an RNeasy Mini kit. RNA quantity and quality was analysed with an ND1000 spectrophotometer (Thermo Fisher Scientific) and with an RNA 6000 Nano kit on an Agilent 2100 Bioanalyser (Agilent Technologies).
DNA microarray. A custom microarray 8615K was designed by eArray (Design ID 33077, Agilent Technologies, https://earray.chem. agilent.com/earray/) using the complete genomic sequence of 81-176, pVir, and pTet (CP000538.1, CP000550.1, CP000549.1; http://www. ncbi.nlm.nih.gov). The design did not include probes for the targets of short or duplicated sequences (CJJ81176_0061, CJJ81176_0770, CJJ81176_0456, CJJ81176_0278, CJJ81176_0368, CJJ81176_0394, CJJ81176_0990, CJJ81176_0991, CJJ81176_0992, CJJ81176_0993, CJJ81176_1741, CJJ81176_1742, CJJ81176_1743, CJJ81176_1744, CJJ81176_0951, CJJ81176_pTet0020, and CJJ81176_pVir0050). cDNA synthesis, labelling and hybridization was performed for four independent biological replicates of each RNA sample and the samples were processed by a one-colour microarray-based prokaryote analysis protocol (FairPlay III Labelling) according to the manufacturer's instructions (Agilent Technologies). Briefly, total RNAs were labelled with a One Colour RNA Spike-kit (Agilent) following measurement by NanoDrop ND-200 to measure the specific activity of the labelled cDNA. Each Cy-3 labelled cDNA (600 ng) was hybridized at 65 uC to a custom chip by using a Gene Expression Hybridization kit (Agilent) according to the manufacturer's instructions. Washings were performed with a Gene Expression Wash Pack (Agilent) with added 0.005 % Triton X-102 and Stabilization and Drying solution (Agilent). Raw data were produced from scanned chips by using Agilent's Feature Extraction program.
Data normalization and statistical analysis. The gene expression microarray data were analysed using R and Bioconductor softwares (Gentleman et al., 2004; R Development Core Team, 2008) . The data were quantile normalized after which an extensive quality analysis was performed for both un-normalized and normalized data. The minimum Pearson's correlation values between biological replicates in each group were between 0.73 and 0.92. Statistical analysis to detect global differences in gene expression between groups was carried out using Bioconductor's Limma package. The chosen thresholds used in filtering the differentially expressed genes were the following: P,0.05 and absolute fold change (FC).1.6 as the cut-off for comparison between unexposed samples (P3 vs 81-176; Group III) and for comparison between P3 unexposed and exposed to ciprofloxacin (Group II). The P,0.001 and absolute FC.6 were cut-offs for the comparison between 81-176 unexposed and exposed to ciprofloxacin (Group I). Two thresholds were selected to list a reasonable number of the most differentially expressed array features because after normalization of the data we found that the responses of the wildtype 81-176 to ciprofloxacin deviated in hierarchical clustering from other groups. With the chosen thresholds, the filtered array features clustered according to the sample groups giving evidence of condition dependent behaviour of the selected features.
Quantitative real-time PCR (RT-qPCR). A selected set of differentially expressed genes from microarray data were verified by RT-qPCR. One microgram of total RNA was reverse transcribed to cDNA as previously described (Selby et al., 2011) . RT-qPCRs were performed with gene specific primers (Table S1 ) in triplicate for three independent samples from each time point, using a previously published amplification protocol (Hyytiäinen et al., 2012) . Fold changes of genes were calculated with the method described by Pfaffl (Pfaffl, 2001 ) using rrs (16S rRNA) as a normalization reference (Han et al., 2008; Hyytiäinen et al., 2012) . Statistical differences in relative gene expression were calculated with one-sample t-tests using SPSS for Windows, Release 15.0.1 software (SPSS).
Microarray accession numbers. Microarray data has been deposited in the Gene Expression Omnibus (GEO) database (http:// www.ncbi.nlm.nih.gov/geo/) under accession numbers GSE41822, GPL16213 and GPL16214.
RESULTS AND DISCUSSION

Characterization of the ciprofloxacin intermediate-resistant variant P3
To allow the comparison of transcriptional responses to ciprofloxacin exposure between the wild-type C. jejuni 81-176 and P3, the variant was further characterized. The P3 strain showed an intermediary resistance with an MIC of 8 mg l 21 and the sequence of gyrA revealed a change at position 268 of the gene causing amino acid change Asp90AAsn in the N-terminal domain of the QRDR. As expected, this mutation was also present in the whole genome sequence of P3. In addition, the genome of the variant P3 differed from the 81-176 parental strain further by two non-synonymous substitutions including in CJJ81176_1105 (coding for a M24/M37 family peptidase) at reference position 1 021 802 and the CJJ81176_1354 (coding for enterochelin ABC transporter) at reference position 1 271 069. Moreover, one deletion was detected comprising CJJ81176_0359 (motA) at position 309 649 which produces a premature stop codon at position 38. These results indicated that the changes under ciprofloxacin treatment were minor in regions outside of QRDR in the genome. In agreement with the motA deletion, we found that the motility of P3 was impaired when compared to the parent strain (data not shown) and TEM revealed that the strain exhibited polar flagella but displayed a straight cell morphology (Fig. S1a) . In a recent study by O'Reagan et al. (2010) on in vitro ciprofloxacin-resistant Salmonella enteritidis also showed reduced motility suggesting that ciprofloxacin resistance may commonly affect bacterial motility. More studies are in progress to find the role of motA and reduced motility in ciprofloxacin resistance as well as if ciprofloxacin resistance also decreases motility among C. jejuni field strains.
Ciprofloxacin exposure and viability of C. jejuni 81-176
The generation time at the exponential growth phase (8 h) was estimated to be approximately 61 min, whilst it increased at the late exponential growth phase (16 h) to approximately 120 min. In vitro growth was equal in the wild-type strain when compared with the resistant P3 variant (Fig. S1b) . Ciprofloxacin has two distinct actions; a bacteriostatic effect at lower concentrations and a lethal effect at higher concentrations (Drlica et al., 2009) . In order to evaluate the effect of ciprofloxacin on the growth and viability of susceptible C. jejuni strain 81-176, a range of ciprofloxacin concentrations (from 0.625 to 8 mg l
21
) in MH broth was tested and the c.f.u. counted after different short-time exposures (from 30 min to 3 h). Our results showed that 1 h of exposure to ciprofloxacin at 8 mg l 21 (646 MIC) did not decrease the wild-type viability, while a one log decrease in c.f.u. was observed after 3 h of exposure (data not shown). Our results contrast with the effects of ciprofloxacin exposure of Pseudomonas aeruginosa (16 MIC for 45 min). This treatment resulted in an approximately 5 % survival rate (Breidenstein et al., 2012) .
Global analysis of differentially expressed genes
To characterize the transcriptional responses with and without ciprofloxacin exposure, we utilized a microarray study for the wild-type strain and resistant variant. As expected, the most extensive amount of transcriptional response was found in the wild-type 81-176 after exposure to 8 mg l 21 ciprofloxacin. In addition, statistical analysis on the hierarchical clustering of the normalized gene expression data revealed that ciprofloxacin-exposed 81-176 clearly deviated from other comparisons (81-176 vs P3 and P3 vs P3+8 mg l 21 ciprofloxacin). To find the most relevant expression changes associated with the ciprofloxacin exposure of 81-176 a higher fold change (FC.6) was selected as a cut-off value compared to .1.6 used for the analysis of the other comparisons, which were more similar.
A summary of the number of differentially expressed genes is presented in Fig. 1 and the corresponding gene responses common in all three group comparisons are listed in Table  S2 . Seven locus tags were common in all comparisons; two of them (CJJ81176 _0948 and CJJ81176_pVir0036), both encoding hypothetical proteins, were upregulated in all group comparisons ( Fig. 1 ; Table S2 ). After 1 h of ciprofloxacin exposure, a total of 320 genes out of 1741 (18.4 %; absolute FC.6, P,0.001) were differentially expressed in the wild-type 81-176 strain, while the total amount of genes responding to ciprofloxacin was 167 out of 1741 ORFs (9.6 %; absolute FC.1.6, P,0.05) in P3 (Fig.  1) . These results indicate that ciprofloxacin exposure activates a wide variety of genes in a susceptible strain and a much more limited general response in the resistant variant. The unique responses to ciprofloxacin consisted of a total of 242 differentially expressed genes (13.9 %) in the wild-type strain 81-176 (Table S3 ). For example, these included the pleiotrophic regulator CmeR, which was downregulated by ciprofloxacin exposure in the wild-type. However, the upregulation of CmeABC efflux pump known to be repressed by CmeR, was not detected after 1 h of ciprofloxacin exposure.
When we compared ciprofloxacin induced gene expression in C. jejuni strain 81-176 with another C. jejuni strain NCTC 11168 (Han et al., 2008) , we found that only a set of genes in 81-176 showed a similar response to ciprofloxacin as NCTC 11168 (Table 1) . For example, we did not find any response in the transcriptional-repair coupling gene mdf as found in the studies of Han et al. (2008) . These gene expression differences may be associated with the strain specific genome composition as well as differences in the experimental conditions (e.g. growth temperature, growth phase, ciprofloxacin concentration, and exposure time). For example, although the ciprofloxacin MICs of both wild-types are similar (0.125 mg l 21 ), 81-176 is resistant to tetracycline (MIC 32 mg l
21
) while NCTC 11168 is susceptible (Hannula & Hänninen, 2008) , which could also partly explain differing responses to DNA repair. However, despite the above-mentioned differences, we cannot rule out that the transcriptional network responding to ciprofloxacin might vary between these two C. jejuni strains.
General responses to ciprofloxacin
Altogether, 52 genes were differentially expressed under ciprofloxacin exposure and common to the parental 81-176 and P3 variant (Fig. 1) . The genes responding similarly to the 1 h ciprofloxacin exposure are presented in Table 2 . These consisted of 25 downregulated genes, including genes involved in the TCA cycle (sdhBC), lipid metabolism (fabH2), nucleotide metabolism (purB-2), or in other cellular processes, in transport or in protein folding (dsbD) ( Table 2 ). In addition, 26 upregulated genes responded similarly to ciprofloxacin in both genetic backgrounds and included gene products functioning in membrane transport, amino acid metabolism (trpEDF), or in translation (operon rpsM-rpmJ). Only one target gene, CJJ81176_1596, annotated as an ATP-sulfurylase family protein, responded to ciprofloxacin differently. It was downregulated in the wild-type but upregulated in the P3 variant. It is noteworthy that none of these general ciprofloxacin responses in 81-176 and its P3 variant were similar to those described earlier for NCTC 11168 (Tables 1 and 2 ).
In addition, the homologue of multidrug antimicrobial extrusion (MATE) protein (CJJ81176_0585) was upregulated by ciprofloxacin exposure in both genetic backgounds, although it was downregulated in unexposed growth conditions in P3 (Table S2 ). The MATE-like transporters have been indicated in several bacteria as multidrug transporters extruding antimicrobials, including ciprofloxacin (Omote et al., 2006) . However, the inactivation of a MATE-transporter (Cj0560) was not shown to have any effect on ciprofloxacin susceptibility in C. jejuni (Ge et al., 2005) . Therefore, the activation of MATE protein by ciprofloxacin might indicate its modest impact on ciprofloxacin extrusion in 81-176 and its variant.
DNA replication and recombination
When we compared the wild-type 81-176 and P3 in unexposed control growth conditions, the differentially expressed genes consisted of 86 unique responses out of a total of 124 responses in P3 (Fig. 1, group III) . Interestingly, the DNA replication and repair genes were downregulated overall in the P3 variant (Fig. 2a, Table S4 ). These genes included rnhB which encodes RNase HII, as well as dnaQ and CJJ81176_0612, encoding the epsilon subunit and a putative delta' subunit of the DNA polymerase III holoenzyme, respectively. While most genes presented in Fig. 2(a) act in DNA replication, the two DNA polymerase III subunits as well as the downregulated Holliday junction ATP-dependent DNA helicase encoded by the ruvB gene (CJJ81176_1364) may also be involved in homologous recombination. Downregulation of the RuvB homologue could decrease strand exchange reactions in homologous recombination in the P3. The downregulation of dnaQ and ruvB was confirmed by RT-qPCR (Fig. 2a) and thus the results were consistent with our microarray data. Gene products involved in processing double-stranded DNA during homologous recombination were clearly downregulated in the wild-type strain 81-176 by ciprofloxacin exposure (Fig. 3a) . These included the recB (addA) gene that encodes a protein recognizing and processing dsDNA and homologues of the ruvA and recG gene products which are involved in Holliday junction formation and dsDNA separation in E. coli. However, although we could not confirm the downregulation of the recG gene by RT-qPCR, another study has also indicated that ciprofloxacin exposure decreased both recG and LexAindepentent ruvA mRNAs in P. aeruginosa (Cirz et al., 2006) . Furthermore, we observed that the mRNAs of dnaX and dnaE, gene products which are involved in DNA replication and in homologous recombination, were downregulated in the wild-type strain 81-176 (Fig. 3a) . Downregulation of the dnaE gene by ciprofloxacin was also observed in C. jejuni NCTC 11168 (Table 1; Han et al., 2008). In contrast, ciprofloxacin exposure increased the expression of DNA polymerase I (polA) suggesting that DNA replication and repair are activated in the resistant P3 variant (Fig. 3b) . In addition, the homologue of RecR (CJJ81176_1279) responsible for damage repair and homologous recombination in E. coli, was downregulated in P3 (Fig. 3b) . It was the only downregulated DNA repair target gene under ciprofloxacin exposure in the P3 variant and the result was confirmed by RT-qPCR (Fig. 3b) . Although we did not see any altered expression of RecA recombinase, the homologue of C. jejuni single-stranded DNA (ssDNA)-binding (SSB) protein, was upregulated in the wild-type (Fig. 3a) . The upregulation of SSB was consistent with ciprofloxacin exposure in H. influenzae (Gmuender et al., 2001) . Furthermore, the upregulation of SSB might limit the recombination by displacing RecA from ssDNA as shown in S. pneumoniae (Steffen et al., 2002) .
Interestingly, dprA was downregulated in unexposed growth conditions in the P3 variant and this was confirmed by RT-qPCR (Fig. 2a) . Furthermore, analysis of additional time points showed that the downregulation of dprA in P3 was independent of the growth phase (Fig. 2b) . In other bacteria, DprA has been suggested to assist binding of the RecA protein to ssDNA during the recombination process (Mortier-Barrière et al., 2007) . Inactivation of the dprA gene reduced the natural transformation capacity of the C. jejuni strain NCTC 11168 (Takata et al., 2005) . Though C. jejuni is naturally transformable and ciprofloxacin resistance evolves with relatively high frequency, the P3 variant seemed to downregulate the DprA recombination protein. Ló pez et al. (2007) suggested that fluoroquinolones might accelerate genetic exchange in treated bacteria and thus increase the probability of developing new acquired antibiotic resistance by increasing recombination. In contrast, our results showed that molecular responses to ciprofloxacin reduced the recombination processes, and that in the P3 resistant variant, genomic maintenance is more likely than extensive recombination. In summary, while ciprofloxacin exposure evidently downregulates recombination in both genetic backgrounds, factors involved in DNA replication are downregulated in the wild-type, but upregulated in the P3 resistant variant.
Ciprofloxacin exposure and DNA supercoiling Topoisomerase I, encoded by the topA gene, acts to relax negatively supercoiled DNA thus changing DNA conformation. TopA was downregulated under ciprofloxacin exposure in the wild-type 81-176 and this result was confirmed by RT-qPCR (Fig. 3a) . This result is in accordance with decreased topA transcription seen in other pathogens after ciprofloxacin challenge (Cirz et al., 2007; Marrer et al., 2006) . However, the expression of topA was not changed by ciprofloxacin in P3, which is most likely explained by the fact that the mutation Asp90AAsn in GyrA maintains the DNA supercoiling homeostasis (Han et al., 2012) . We detected no mutations in the topA gene, similar to the result reported by Han et al. (2012) . Furthermore, levels of gyrA or gyrB expression were not significantly altered in the wild-type or P3 (data not shown). Overall, ciprofloxacin exposure decreases the expression of topA thus favouring the maintenance of negative supercoiled DNA in the wild-type C. jejuni.
Ciprofloxacin and NER
NER is a DNA repair process in which a small region of the strand surrounding the damage is removed from the DNA helix. The small gap left in the DNA helix is then filled by the sequential action of DNA polymerase and DNA ligase. NER recognizes a wide range of substrates, including damage caused by UV irradiation and chemicals. We found that the uvrD-like gene, that encodes a putative ATPdependent DNA helicase (CJJ81176_0798) and is likely acting in the post-incision events of NER, was upregulated under ciprofloxacin exposure in both the wild-type and resistant P3 strains (Fig. 3a, b) . The UvrD-like orthologue has also been shown to be upregulated by ciprofloxacin exposure in Mycobacterium tuberculosis (O'Sullivan et al., 2008) . In addition, another gene, a homologue of uvrA, was upregulated in the resistant P3 variant and RT-qPCR verified this result (Fig. 3b) . UvrA upregulation by ciprofloxacin has also been reported in S. aureus and H. influenzae (Cirz et al., 2007; Gmuender et al., 2001) . The orthologues of UvrA are functioning at the recognition step of DNA damage in NER by global genome repair or by transcription coupled repair together with the Mfd factor. Interestingly, while the previous study by Han et al. (2008) showed the upregulation of mfd under ciprofloxacin exposure in C. jejuni NCTC 11168, we observed upregulation of different factors functioning in the same repair system. The differences in these two studies may be partially explained by strain specific characteristics, ciprofloxacin concentration, and exposure time.
BER damage recognition factors are differentially regulated in P3
BER is the major repair pathway removing DNA damage. These include recognition and repair modified bases, such as oxidized or ring-saturated bases, alkylated and deaminated bases, and some types of mismatches. Interestingly, we noticed that the nth and mutY genes which have a putative role in recognition of these altered bases were downregulated in unexposed growth conditions in P3 (Fig.  2a) . The mutY gene product is related to the monofunctional glycosylases that remove deaminated, alkylated, or mismatched bases creating apurinic or apyrimidinic (AP) sites, and nth encodes a bifunctional glycosylase that removes oxidized bases and possesses an additional 39-APlyase activity. The downregulation of mutY was validated by RT-qPCR (Fig. 2a) and with additional time points we were able to show that the downregulation of mutY was growth-phase independent in P3 (Fig. 2c) . Our microarray results, in contrast, indicated that under ciprofloxacin exposure, the ung gene which encodes a uracil-DNA glycosylase (Gaasbeek et al., 2009) and CJJ81176_0986 which encodes a putative uracil-DNA glycosylase, were upregulated in the P3 variant (Fig. 3b ). This result suggests that different factors of the BER system are activated in the presence of ciprofloxacin. The different responses of MutY and Ung in the P3 variant are particularly interesting, as both of these glycosylases are monofunctional, but the MutY response was associated with the genetic background and the Ung response with the ciprofloxacin exposure. Our results suggest that the factors in the BER system were differentially expressed at the stage of damage recognition in P3.
The MMR system: a non-functional system in C. jejuni MMR has been suggested to be a non-functional DNA repair mechanism in C. jejuni, because of the lack of MutL and MutY orthologues resulting in incomplete damage recognition (Gaasbeek et al., 2009) . However, C. jejuni has a homologue of the exoribonuclease VII large subunit, xseA (CJJ81176_0347), which was repressed in unexposed growth conditions in P3 (Fig. 2a) , but upregulated by ciprofloxacin in the wild-type 81-176 (Fig. 3a) . XseA has been associated with the degradation of ssDNA in other bacteria. This result suggests that the P3 variant might have lower specificity to degrade ssDNA, while ciprofloxacin induces the degradation process in the wild-type 81-176. However, the function of XseA homologue remains to be elucidated in C. jejuni.
Other DNA modifying factors are upregulated by ciprofloxacin
In prokaryotes, the major role of DNA methylation is to protect host DNA against degradation by restriction enzymes. Two putative methyltransferases (CJJ81176_0240 and CJJ81176_1454) were downregulated under unexposed growth conditions in the P3 variant (Fig. 2a) . However, our results indicated that ciprofloxacin induced the expression of the putative D12 class N6 adenine-specific DNA methyltransferase in both genetic backgrounds (Fig.  3a, b) . In addition, the putative site-specific methyltransferase (CJJ81176_1454) was induced in the P3 strain and the putative TatD family hydrolase (CJJ81176_0672) in the wild-type strain by ciprofloxacin (Fig. 3a, b) . The increased levels of the two genes were validated by RT-qPCR in the wild-type (CJJ81176_0672; Fig. 3a ) and the P3 variant (CJJ81176_0240; Fig. 3b ). Therefore, ciprofloxacin exposure generally increases the expression of DNA modifying enzymes although the exact function of these factors remains to be elucidated.
CONCLUSIONS
In this study, we showed that when C. jejuni encounters a relatively high concentration of ciprofloxacin, the gene expression response in the DNA replication and repair systems mimicked those observed in other bacteria. Even without a functional SOS response, and a putative functional mismatch repair system, we suggest that the observed changes in DNA repair systems are programmed to maintain genome structure and diminish lethal DNA damage in C. jejuni. Furthermore, the resistant strain employs the same DNA repair mechanism as the wild-type in the presence of ciprofloxacin. The activated or repressed factors in each DNA repair system, however, seem to vary according to ciprofloxacin susceptibility. The summary of responses to ciprofloxacin exposure is presented in Fig. 4 . Strikingly, none of the DNA replication or repair genes that respond to oxidant exposure were found in our microarray data among the differentially expressed genes. As reported by Palyada et al. (2009) , oxidative stress downregulated a putative ATP-dependent DNA ligase, UvrC, and the chromosomal replication initiator protein DnaA. Therefore, ciprofloxacin seems to affect the DNA repair pathways quite distinctly compared to what was observed with oxidant exposure in C. jejuni. In addition, our results suggest that DNA repair mechanisms are active in ciprofloxacin-resistant C. jejuni and may explain the persistence of ciprofloxacin-resistant isolates in natural environments. The molecular mechanism of the Asp90AAsn mutation in GyrA that retains DNA supercoiling activity, and the responses to ciprofloxacin exposure in DNA repair systems, inevitably require more functional research. Furthermore, the whole genome sequence analysis of the P3 variant also supports active DNA repair mechanisms because only a few genomic changes were detected.
